Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project

Abdulla, M.; Chandra, Prem; Akiki, Susanna; Aldapt, Mahmood B; Sardar, Sundus; Chapra, Ammar; Nashwan, Abdulqadir J.; Sorio, Claudio; Tomasello, Luisa; Böni, Christian; Yassin, Mohamed A

doi:10.1177/10732748211038429

Cited by 13 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, CML can be divided based on progression into three phases: the chronic phase is when most patients are diagnosed; the accelerated phase characterized by impairment of neutrophil differentiation; and the blast phase in which myeloid cells proliferate uncontrollably, resembling acute leukemia [ 5 , 6 , 8 , 9 ]. The diagnosis of CML involves several steps, starting with a peripheral blood smear that typically shows neutrophilia, followed by bone marrow biopsy, and finally, testing for the BCR-ABL fusion gene or mRNA that are confirmatory for the disease [ 10 , 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Applications of Machine Learning in Chronic Myeloid Leukemia

et al. 2023

Self Cite

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by dysregulated growth and the proliferation of myeloid cells in the bone marrow caused by the BCR-ABL1 fusion gene. Clinically, CML demonstrates an increased production of mature and maturing granulocytes, mainly neutrophils. When a patient is suspected to have CML, peripheral blood smears and bone marrow biopsies may be manually examined by a hematologist. However, confirmatory testing for the BCR-ABL1 gene is still needed to confirm the diagnosis. Despite tyrosine kinase inhibitors (TKIs) being the mainstay of treatment for patients with CML, different agents should be used in different patients given their stage of disease and comorbidities. Moreover, some patients do not respond well to certain agents and some need more aggressive courses of therapy. Given the innovations and development that machine learning (ML) and artificial intelligence (AI) have undergone over the years, multiple models and algorithms have been put forward to help in the assessment and treatment of CML. In this review, we summarize the recent studies utilizing ML algorithms in patients with CML. The search was conducted on the PubMed/Medline and Embase databases and yielded 66 full-text articles and abstracts, out of which 11 studies were included after screening against the inclusion criteria. The studies included show potential for the clinical implementation of ML models in the diagnosis, risk assessment, and treatment processes of patients with CML.

show abstract

Section: Introductionmentioning

confidence: 99%

Applications of Machine Learning in Chronic Myeloid Leukemia

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…atherosclerosis themselves. Furthermore, obesity might influence pharmacokinetics of drugs used in MPN treatment, although data is limited (30)(31)(32)(33).…”

Section: Discussionmentioning

confidence: 99%

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Felser

Rogahn²,

Coutre³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPhysical activity (PA) is a non-pharmacological approach to alleviate symptom burden and improve health-related quality of life (HrQoL) in cancer patients (pts). Whether pts with myeloproliferative neoplasms (MPN) PA behavior changes due to symptom burden and/or knowledge of the putative beneficial effects of PA has not yet been investigated.MethodsWe performed a large questionnaire study in MPN pts. Self-reported PA behavior and potential influencing factors of 634 MPN pts were analyzed. Questionnaires were used to assess demographics, anxiety, severity of symptoms, HrQoL, current level of everyday and sports activities, and the level of information regarding the importance/possibilities of PA. According to their PA, the pts were assigned to the three groups: “inactive”, “non-targeted active”, and “sporty active” and compared with each other.ResultsKey findings are that in 73% of the pts, the disease had an impact on PA, with 30% of pts reducing their PA. The prevalence of anxieties (e.g., occurrence of thrombosis and bleeding) regarding PA was 45%. Sporty active pts had a lower symptom burden and better HrQoL (p ≤ 0.001) compared to the other groups. Inactive pts were significantly older and had a higher body mass index than sporty active pts. Inactive and non-targeted active pts felt less informed about the importance/possibilities of PA (p = 0.002).ConclusionOur results suggest that especially older and non-sporty MPN pts could benefit from motivational as well as disease-specific PA information. This study was registered at the German Registry of Clinical Trials, DRKS00023698.

show abstract

“…It is still unclear what is the best available therapy for those patients and whether to start with imatinib [ 10 ] upfront or dasatinib/nilotinib [ 11 ], and it remains one of the unmet needs and unanswered questions regarding CML treatment in different conditions, which we have shed the light on in previous articles such as CML with obesity [ 12 ], obesity-related surgeries [ 13 ], intermittent fasting [ 14 ], hepatitis [ 15 ], and tuberculosis [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Radioactive Iodine-Induced Chronic Myeloid Leukemia in a Patient With Graves' Disease: A Case Report

Yasin¹,

Abu-Tineh²,

Alshurafa³

et al. 2023

Cureus

View full text Add to dashboard Cite

Therapy-related leukemia is an increasing concern in hematology. One of these substances that showed to increase the incidence of leukemia is radioactive iodine (RAI). We report here a case of radioactive iodineinduced chronic myeloid leukemia (CML) in a patient with Graves' disease, although most cases in the literature were for thyroid cancer. Also, our patient received a very low dose, which is unique compared to previous case reports in the literature.

show abstract

Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project

Cited by 13 publications

References 32 publications

Applications of Machine Learning in Chronic Myeloid Leukemia

Applications of Machine Learning in Chronic Myeloid Leukemia

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Radioactive Iodine-Induced Chronic Myeloid Leukemia in a Patient With Graves' Disease: A Case Report

Contact Info

Product

Resources

About